References
Redfield MM, Jacobsen SJ, Burnett JC Jr, et al.: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194–202.
Gottdiener JS, McClelland RL, Marshall R, et al.: Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002, 137:631–639.
Senni M, Redfield MM: Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol 2001, 38:1277–1282.
Bernal J, Pitta SR, Thatai D: Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention. Am J Cardiovasc Drugs 2006, 6:373–381.
Cleland JG, Tendera M, Adamus J, et al.: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338–2345.
Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777–781.
Carson P, Massie BM, McKelvie R, et al.: The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005, 11:576–585.
McMurray JJ, Carson PE, Komajda M, et al.: Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008, 10:149–156.
National Heart, Lung, and Blood Institute: Aldosterone antagonist therapy for adults with heart failure and preserved systolic function (TOPCAT). Available at http://clinicaltrials.gov/ct2/show/NCT00094302?term=TOPCAT&rank=1. Accessed March 2009.
Connelly K, Kelly DJ, Kim S, et al.: The direct renin inhibitor, aliskiren, improves cardiac function via direct renin inhibition and via renin receptor modulation in a rodent model of diabetic diastolic heart failure [abstract]. Circulation 2008, 118(Suppl 2):S1166.
Krum H, Connelly K, Zhang M, et al.: Directly targeting myocardial fibrosis with FT-011 improves cardiac remodelling in experimental diabetic cardiomyopathy [abstract]. Circulation 2008, 118(Suppl 2):S283.
Little WC, Zile MR, Kitzman DW, et al.: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005, 11:191–195.
Rights and permissions
About this article
Cite this article
Krum, H. Does angiotensin receptor blockade improve outcomes in patients with heart failure and preserved ejection fraction? Results of the I-PRESERVE study. Curr Heart Fail Rep 6, 65–67 (2009). https://doi.org/10.1007/s11897-009-0011-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11897-009-0011-y